Kronos Bio Inc (KRON) concluded trading on Thursday at a closing price of $0.71, with 9.0 million shares of worth about $6.39 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -27.04% during that period and on May 01, 2025 the price saw a loss of about -19.98%. Currently the company’s common shares owned by public are about 60.46M shares, out of which, 39.23M shares are available for trading.
Stock saw a price change of -17.03% in past 5 days and over the past one month there was a price change of -11.58%. Year-to-date (YTD), KRON shares are showing a performance of -24.80% which decreased to -28.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.69 but also hit the highest price of $1.60 during that period. The average intraday trading volume for Kronos Bio Inc shares is 151.82K. The stock is currently trading -14.43% below its 20-day simple moving average (SMA20), while that difference is down -19.20% for SMA50 and it goes to -26.69% lower than SMA200.
Kronos Bio Inc (NASDAQ: KRON) currently have 60.46M outstanding shares and institutions hold larger chunk of about 23.35% of that.
The stock has a current market capitalization of $43.55M and its 3Y-monthly beta is at 1.76. It has posted earnings per share of -$1.43 in the same period. It has Quick Ratio of 7.54 while making debt-to-equity ratio of 0.28. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KRON, volatility over the week remained 7.95% while standing at 6.84% over the month.
Analysts are in expectations that Kronos Bio Inc (KRON) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same.
Coverage by Piper Sandler stated Kronos Bio Inc (KRON) stock as a Neutral in their note to investors on November 14, 2024, suggesting a price target of $1 for the stock. Stock get a Buy rating from H.C. Wainwright on June 24, 2021.
